Mraz Amerine & Associates Inc. Sells 260 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Mraz Amerine & Associates Inc. lessened its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 4.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,311 shares of the biotechnology company’s stock after selling 260 shares during the period. Mraz […]

Related Keywords

United States ,Ariel Hurley ,Stifel Nicolaus ,Jeffreyw Albers ,Morgan Stanley ,Cutler Group ,Wells Fargo Company ,Lazard Asset Management ,Securities Exchange Commission ,Blueprint Medicines Co ,Mraz Amerine Associates Inc ,Nasdaq ,Blueprint Medicines Corporation ,Needham Company ,Financial Services Group Inc ,Mraz Amerine ,Blueprint Medicines ,Free Report ,Services Group ,Asset Management ,Dark Forest Capital Management ,Get Free Report ,Exchange Commission ,Director Jeffrey ,Medicines Corporation ,Blueprint Medicines Daily ,Nasdaq Bpmc ,Bpmc ,Medical ,Sec Filings ,13f ,Hedge Fund Holdings ,Institutional Investor Holdings ,